The bioactivity and bioavailability of IGF-1 are regulated by IGF-1 binding proteins (IGFBPs) (265), and the increased IGF-1 levels observed in some AD patients might be functionally suppressed by correspondingly elevated IGFBP3 levels. Here, IGF1 is linked to Alzheimer disease.